[1]夏 琴.肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病疗效研究[J].陕西中医,2019,(4):469-471.
　XIA Qin..Feitai capsule combined with linezolid in the treatment of extensively drugresistant tuberculosis[J].,2019,(4):469-471.
点击复制

肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年4期
页码:
469-471
栏目:
临床研究
出版日期:
2019-04-05

文章信息/Info

Title:
Feitai capsule combined with linezolid in the treatment of extensively drugresistant tuberculosis
文章编号:
DOI:10.3969/j.issn.10007369.2019.04.019
作者:
夏 琴
陕西省咸阳市中心医院药学部 (咸阳 712000)
Author(s):
XIA Qin.
Department of Pharmacy，Xianyang Central Hospital of Shaanxi Province（Xianyang 712000）
关键词:
广泛性耐药结核病; 肺泰胶囊; 利奈唑胺; 不良反应; 临床效果; 安全性
Keywords:
Key words Extensively drugresistant tuberculosis; Feitai capsule; Linezolid; Adverse reactions; Clinicl effect; Safety
分类号:
R52
文献标志码:
A
摘要:
摘 要 目的：探讨肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病患者的临床效果以及不良反应。方法：收集106例广泛性耐药结核病患者，按照数字随机表法分为两组各53例，研究组在利奈唑胺治疗的基础上联合使用肺泰胶囊，对照组仅使用利奈唑胺进行治疗，对比观察两组患者的临床效果和治疗安全性。结果：研究组患者在治疗1、3、6个月后痰菌阴转率分别为67.92%、84.91%、98.11%，均明显高于对照组52.83%、69.81%和75.47%，组间比较差异具有统计学意义（P＜0.05）；治疗后研究组患者肺部病灶吸收、空洞闭合和临床症状改善情况均明显优于对照组改善情况，改善时间短于对照组改善时间，差异均具有统计学意义（P＜0.05）；研究组不良事件发生率为16.98%，明显少于对照组32.08%，差异具有统计学意义（P＜0.05）。结论：肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病患者能够有效的促进肺部病灶吸收和空洞闭合，加快痰菌转阴，降低不良反应，效果显著。
Abstract:
Abstract Objective：To investigate the clinical efficacy and adverse reactions of Feitai capsule combined with linezolid in the treatment of extensively drugresistant tuberculosis. Methods：106 patients with extensively drugresistant tuberculosis were divided into two groups according to the method of digital random table，53 cases in each group. The clinical effect and safety of treatment. Results ：The sputum negative conversion rates of the study group were 67.92%，84.91% and 98.11% respectively after 1，3 and 6 months of treatment，which were significantly higher than those of the control group (52.83%，69.81% and 75.47%). The difference between the two groups was statistically significant (P＜0.05). The incidence of gastrointestinal reaction，liver damage，leukopenia，gout and other adverse reactions in the study group was 16.98%，which was significantly less than that in the control group (32.08%). The difference was statistically significant (P＜0.05). Conclusion： Feitai capsule combined with linezolid in the treatment of extensively drugresistant tuberculosis patients can effectively promote the absorption of lung lesions and cavity closure，accelerate sputum negative，reduce adverse reactions，the effect is significant，can be widely used.

参考文献/References:

[1] 王爱民，王小军，董雪松.利奈唑胺联合常规化疗治疗广泛耐药肺结核的疗效观察 [J].现代药物与临床，2016，31(10):16521656.
[2] 杨克西，王建东.口服利奈唑胺在治疗耐药结核中疗效及安全性临床观察 [J].临床肺科杂志，2017，22(1):2528.
[3] Pym AS，Diacon A H，Tang S J，et al.Bedaquiline in the treatment of multidrugand extensively drugresistant tuberculosis. [J].European Respiratory Journal，2016，47(2):564.
[4] 陈 爽，焦雪峰，杨海鹏，等.利奈唑胺治疗耐多药和广泛耐药肺结核的疗效和安全性的Meta分析 [J].临床药物治疗杂志，2017，15(4):3946.
[5] 杨 铭，梁宗安，袁 平，等.利奈唑胺治疗耐药结核病的临床疗效和安全性评估 [J].四川医学，2017，38(11):12291233.
[6] Shah NS，Auld S C，Brust J C M，et al.Transmission of Extensively DrugResistant Tuberculosis in South Africa [J].New England Journal of Medicine，2017，376(3):243247.
[7] 汪晓芹,杜超英,阳绪容,等.纤维支气管镜介入治疗肺结核疗效观察及对痰菌阴转率影响研究 [J].陕西医学杂志,2018,47(3):317319.
[8] 闫琼红,吴西娟.利福喷丁对肺结核患者的治疗效果及对血清IL6、IFNγ、CA125的影响 [J].陕西医学杂志,2017,46(12):17671768.
[9] 张春晓，王永亮，鲁广建，等.耐多药肺结核患者呼吸道感染的病原菌分布与耐药性分析 [J].中华医院感染学杂志，2016，26(7):14891491.〖ZK)〗
[10] 唐怡敏，邓国防，叶涛生，等.利奈唑胺治疗耐多药结核病的现状及认识 [J]. 中国防痨杂志，2017，39(6):659663.
[11] 于春宝，李学政，张先欣，等. 肺结核合并慢性阻塞性肺病患者的临床特点及抗结核药物的耐药性分析 [J]. 山东医药，2017，57(1):7476.
[12] 毕占友，郝 军，陈忠建，等. 微卡联合化学药物治疗多耐药结核病临床疗效分析 [J]. 陕西医学杂志，2018，47(4)：509511.
[13] Migliori G B，Matteelli A，Cirillo D，et al.Diagnosis of multidrugresistant tuberculosis and extensively drugresistant tuberculosis：Current standards and challenges [J].Canadian Journal of Infectious Diseases & Medical Microbiology，2016，19(2):169172.
[14] 李晓红，韩 华，温明超，等.利奈唑胺治疗肺部MRSA感染效果及其对炎性指标、内皮功能等的影响 [J].疑难病杂志，2018，17(1):1417.

更新日期/Last Update: 2019-04-24